Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Sell Roche s AmpliChip CYP450 Assay

NEW YORK, Nov. 28 (GenomeWeb News) - Laboratory Corporation of America will sell Roche Diagnostics' Cytochrome AmpliChip P450 2D6/2C19 genotyping and phenotyping assay, the company said today.

 

The assay, approved by the US Food and Drug Administration in January, is designed to identify multiple genetic variants in two cytochrome P450 genes, CYP2D6 and CYP2C19, which metabolize 40 to 45 percent of all prescription drugs, including antidepressants, pain relievers, and cardiovascular agents.

 

This summer, the reference lab helped validate the chip for Roche, and worked with the Swiss diagnostic giant evaluate its research leukemia microarray, which is currently in development.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.